Indications and uses
To relieve the symptoms of fatigue.
Kali silicatum
- Manufacturer
- Washington Homeopathic Products
- Effective date
- 2015-07-01
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-01 02:08:46
Label at a glance#
ProductKali silicatum
Active ingredientPOTASSIUM SILICATE
Label structure8 sections
Dosage and administration
Adults: Dissolve 3 to 5 under the tongue three times a day or as directed by Lic. Practitioner. Take at greater intervals as condition subsides. Children: Dissolve 3 to 5 under the tongue three times a day or as directed by Lic. Practitioner. Take at greater intervals as condition subsides.
Label contents#
Full prescribing information#
ACTIVE INGREDIENTS
KALI SIL
USES
To relieve the symptoms of fatigue.
KEEP OUT OF REACH OF CHILDREN
Keep this and all medicines out of reach of children.
INDICATIONS
Indications:
KALI SIL Fatigue
STOP USE AND ASK DOCTOR
If symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.
DIRECTIONS
Adults: Dissolve 3 to 5 under the tongue three times a day or as directed by Lic. Practitioner. Take at greater intervals as condition subsides. Children: Dissolve 3 to 5 under the tongue three times a day or as directed by Lic. Practitioner. Take at greater intervals as condition subsides.
INACTIVE INGREDIENTS
Sucrose/Lactose
PRINCIPAL DISPLAY PANEL
The OTC potency range of KALI SIL is 2x–30x, 1c–30c, 200c, 1m, 10m, 50m, and CM.
Availability is subject to change.
All WHP single remedies are made to order; thus, the labels are printed on the same label stock as the orders are filled.
‘Bottle Size’ and ‘Potency’ vary on the label depending on customer choice.
Standard bottle sizes for pellet-form remedies are 2 dram, 4 dram, 1 ounce, 2 ounce, and 4 ounce.
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68428-966-03 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-77fd-d83d-e063-dadaa90ab31f | DRUG FACTS |
| 68428-966-05 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-77fd-d83d-e063-dadaa90ab31f | DRUG FACTS |
| 68428-966-06 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-77fd-d83d-e063-dadaa90ab31f | DRUG FACTS |
| 68428-966-11 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-77fd-d83d-e063-dadaa90ab31f | DRUG FACTS |
| 68428-966-12 | 2025-01-30 | C162847 | 48780-1 | 2cef2736-77fd-d83d-e063-dadaa90ab31f | DRUG FACTS |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68428-966-03 | Kali silicatum | 75 in 1 VIAL, GLASS | PELLET | 75 | 1 | |
| 68428-966-05 | Kali silicatum | 150 in 1 VIAL, GLASS | PELLET | 150 | 1 | |
| 68428-966-06 | Kali silicatum | 1200 in 1 BOTTLE, GLASS | PELLET | 1200 | 1 | |
| 68428-966-11 | Kali silicatum | 300 in 1 BOTTLE, GLASS | PELLET | 300 | 1 | |
| 68428-966-12 | Kali silicatum | 600 in 1 BOTTLE, GLASS | PELLET | 600 | 1 |
DailyMed Dashboard NDC Coverage#
Products#
Every source-derived product name is available through these pages.
- Kali silicatum
- POTASSIUM SILICATE
- POTASSIUM CATION
- SUCROSE
- LACTOSE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 68428-966 | 68428-966-03, 68428-966-05, 68428-966-11, 68428-966-12, 68428-966-06 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| POTASSIUM SILICATE | J86L1GUL6K | ACTIB |
| SUCROSE | C151H8M554 | IACT |
| LACTOSE | J2B2A4N98G | IACT |
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 4abf1e41-8f6b-4501-a8ca-fc323633f785 | e5787f0c-1fb2-40d9-805f-dcee15e30cf8 | 2015-07-01 | Warnings | 4abf1e41-8f6b-4501-a8ca-fc323633f785 e5787f0c-1fb2-40d9-805f-dcee15e30cf8 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.